002399 海普瑞
已收盘 11-22 15:00:00
资讯
新帖
简况
海普瑞(09989)下跌5.04%,报3.96元/股
金融界 · 15:06
海普瑞(09989)下跌5.04%,报3.96元/股
海普瑞(002399)10月31日主力资金净卖出324.40万元
证券之星 · 11-01
海普瑞(002399)10月31日主力资金净卖出324.40万元
海普瑞(09989)下跌5.42%,报4.19元/股
金融界 · 10-31
海普瑞(09989)下跌5.42%,报4.19元/股
图解海普瑞三季报:第三季度单季净利润同比增487.43%
证券之星 · 10-31
图解海普瑞三季报:第三季度单季净利润同比增487.43%
海普瑞(002399.SZ)发布前三季度业绩,净利润7.8亿元,同比增长444.89%
智通财经 · 10-30
海普瑞(002399.SZ)发布前三季度业绩,净利润7.8亿元,同比增长444.89%
《业绩》海普瑞(09989.HK)首三季纯利大增逾4.4倍至7.8亿人币
阿斯达克财经 · 10-30
《业绩》海普瑞(09989.HK)首三季纯利大增逾4.4倍至7.8亿人币
海普瑞(09989)发布前三季度业绩 归母净利润7.8亿元 同比增加444.89%
智通财经 · 10-30
海普瑞(09989)发布前三季度业绩 归母净利润7.8亿元 同比增加444.89%
海普瑞(09989)下跌10.6%,报4.3元/股
金融界 · 10-09
海普瑞(09989)下跌10.6%,报4.3元/股
海普瑞(09989)出现大手卖出78.95万股,成交价$5.59,涉资441.33万
阿斯达克财经 · 10-08
海普瑞(09989)出现大手卖出78.95万股,成交价$5.59,涉资441.33万
海普瑞(09989)股价显著上升12.179%,现价港币$5.25
阿斯达克财经 · 10-07
海普瑞(09989)股价显著上升12.179%,现价港币$5.25
海普瑞(09989)上涨10.16%,报4.12元/股
金融界 · 09-30
海普瑞(09989)上涨10.16%,报4.12元/股
大摩:维持海普瑞“与大市同步”评级 目标价降至3.5港元
智通财经 · 09-17
大摩:维持海普瑞“与大市同步”评级 目标价降至3.5港元
大摩:维持海普瑞(09989)“与大市同步”评级 目标价降至3.5港元
智通财经网 · 09-17
大摩:维持海普瑞(09989)“与大市同步”评级 目标价降至3.5港元
海普瑞新提交2件商标注册申请
证券之星 · 09-09
海普瑞新提交2件商标注册申请
营收利润双增长,剖析海普瑞(002399.SZ/9989.HK)稳中求进的增长底色
格隆汇 · 09-09
营收利润双增长,剖析海普瑞(002399.SZ/9989.HK)稳中求进的增长底色
海普瑞(002399)9月3日主力资金净卖出100.34万元
证券之星 · 09-04
海普瑞(002399)9月3日主力资金净卖出100.34万元
海普瑞(002399)9月2日主力资金净卖出346.82万元
证券之星 · 09-03
海普瑞(002399)9月2日主力资金净卖出346.82万元
《业绩》海普瑞(09989.HK)中期纯利6.64亿人民币增4.38倍 不派息
阿斯达克财经 · 09-01
《业绩》海普瑞(09989.HK)中期纯利6.64亿人民币增4.38倍 不派息
海普瑞(002399)2024年中报简析:营收净利润同比双双增长
证券之星 · 09-01
海普瑞(002399)2024年中报简析:营收净利润同比双双增长
海普瑞最新公告:上半年净利润6.64亿元 同比增长438.05%
证券之星 · 08-30
海普瑞最新公告:上半年净利润6.64亿元 同比增长438.05%
加载更多
公司概况
公司名称:
深圳市海普瑞药业集团股份有限公司
所属行业:
医药制造业
上市日期:
2010-05-06
主营业务:
深圳市海普瑞药业集团股份有限公司是一家从事肝素产业链、生物大分子CDMO和创新药物的投资、开发和商业化的企业。主要产品和服务包括依诺肝素钠制剂、肝素钠和依诺肝素钠原料药,以及大分子药物CDMO服务。本公司是全球产销规模最大、也是我国唯一同时取得美国FDA认证和欧盟CEP认证的肝素钠原料药生产企业。公司作为欧盟依诺肝素生物类似物市场的先驱者,公司已在知名医院以及医学专家中树立了良好的品牌声誉。
发行价格:
148.00
{"stockData":{"symbol":"002399","market":"SZ","secType":"STK","nameCN":"海普瑞","latestPrice":10.8,"timestamp":1732259037000,"preClose":11.38,"halted":0,"volume":4266420,"delay":0,"floatShares":1247000000,"shares":1467000000,"eps":-0.0998,"marketStatus":"已收盘","marketStatusCode":5,"change":-0.58,"latestTime":"11-22 15:00:00","open":11.4,"high":11.44,"low":10.8,"amount":47358000,"amplitude":0.0562,"askPrice":10.81,"askSize":30,"bidPrice":10.8,"bidSize":105,"shortable":0,"etf":0,"ttmEps":-0.0998,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1732498200000},"adr":0,"adjPreClose":11.38,"symbolType":"stock","openAndCloseTimeList":[[1732239000000,1732246200000],[1732251600000,1732258800000]],"highLimit":12.52,"lowLimit":10.24,"ibTradeSell":false,"ibTradeBuySell":true,"totalEquity":1467296204,"pbRate":1.38,"roa":"--","roe":"6.43%","epsLYR":-0.5338,"committee":-0.07635,"marketValue":15847000000,"floatMarketCap":13470000000,"peRate":-108.216435,"changeRate":-0.051,"turnoverRate":0.0034,"status":1},"requestUrl":"/m/hq/s/002399","defaultTab":"news","newsList":[{"id":"2485284865","title":"海普瑞(09989)下跌5.04%,报3.96元/股","url":"https://stock-news.laohu8.com/highlight/detail?id=2485284865","media":"金融界","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2485284865?lang=zh_cn&edition=full","pubTime":"2024-11-22 15:06","pubTimestamp":1732259197,"startTime":"0","endTime":"0","summary":"11月22日,海普瑞(09989)盘中下跌5.04%,截至15:06,报3.96元/股,成交326.25万元。深圳市海普瑞药业集团股份有限公司的主要业务是覆盖肝素全产业链、生物大分子CDMO以及创新药物的投资、开发和商业化。通过这三大板块业务的相互协作,公司旨在为全球患者提供安全有效的高质量药物和服务。截至2024年三季报,海普瑞营业总收入40.69亿元、净利润7.8亿元。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://hk.jrj.com.cn/2024/11/22150645571028.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_stock","symbols":["002399","BK0070","BK0239","BK1191","09989","BK0188"],"gpt_icon":0},{"id":"2480161710","title":"海普瑞(002399)10月31日主力资金净卖出324.40万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2480161710","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2480161710?lang=zh_cn&edition=full","pubTime":"2024-11-01 09:21","pubTimestamp":1730424118,"startTime":"0","endTime":"0","summary":"证券之星消息,截至2024年10月31日收盘,海普瑞报收于11.07元,下跌2.47%,换手率0.69%,成交量8.6万手,成交额9513.38万元。近5日资金流向一览见下表:海普瑞融资融券信息显示,融资方面,当日融资买入974.53万元,融资偿还1608.6万元,融资净偿还634.07万元。海普瑞主营业务:肝素产业链、生物大分子CDMO和创新药物的投资、开发及商业化,致力于为全球患者带去高质量的安全有效药物和服务,护佑健康。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024110100010706.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK1191","09989","BK0239","BK0188","002399","BK0070"],"gpt_icon":0},{"id":"2479715999","title":"海普瑞(09989)下跌5.42%,报4.19元/股","url":"https://stock-news.laohu8.com/highlight/detail?id=2479715999","media":"金融界","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2479715999?lang=zh_cn&edition=full","pubTime":"2024-10-31 09:44","pubTimestamp":1730339053,"startTime":"0","endTime":"0","summary":"10月31日,海普瑞(09989)盘中下跌5.42%,截至09:44,报4.19元/股,成交380.93万元。深圳市海普瑞药业集团股份有限公司的主要业务是覆盖肝素全产业链、生物大分子CDMO以及创新药物的投资、开发和商业化。通过这三大板块业务的相互协作,公司旨在为全球患者提供安全有效的高质量药物和服务。截至2024年三季报,海普瑞营业总收入40.69亿元、净利润7.8亿元。10月30日,2024财年三季报归属股东应占溢利7.801亿人民币,同比增长444.89%,基本每股收益0.5317人民币。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://hk.jrj.com.cn/2024/10/31094444768880.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_stock","symbols":["BK0070","09989","BK0188","BK1191","BK0239","002399"],"gpt_icon":0},{"id":"2479075824","title":"图解海普瑞三季报:第三季度单季净利润同比增487.43%","url":"https://stock-news.laohu8.com/highlight/detail?id=2479075824","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2479075824?lang=zh_cn&edition=full","pubTime":"2024-10-31 01:57","pubTimestamp":1730311051,"startTime":"0","endTime":"0","summary":"证券之星消息,海普瑞2024年三季报显示,公司主营收入40.69亿元,同比上升0.14%;归母净利润7.8亿元,同比上升444.89%;扣非净利润4.29亿元,同比上升402.43%;其中2024年第三季度,公司单季度主营收入12.32亿元,同比下降8.8%;单季度归母净利润1.16亿元,同比上升487.43%;单季度扣非净利润9935.89万元,同比上升1631.43%;负债率32.6%,投资收益4.16亿元,财务费用8295.91万元,毛利率33.2%。财报数据概要请见下图:以上内容为证券之星据公开信息整理,由智能算法生成,不构成投资建议。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024103100003026.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["002399","09989"],"gpt_icon":0},{"id":"2479205446","title":"海普瑞(002399.SZ)发布前三季度业绩,净利润7.8亿元,同比增长444.89%","url":"https://stock-news.laohu8.com/highlight/detail?id=2479205446","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2479205446?lang=zh_cn&edition=full","pubTime":"2024-10-30 19:43","pubTimestamp":1730288597,"startTime":"0","endTime":"0","summary":"智通财经APP讯,海普瑞(002399.SZ)发布2024年三季度报告,前三季度,公司实现营业收入40.69亿元,同比增长0.14%。归属于上市公司股东的净利润7.8亿元,同比增长444.89%。归属于上市公司股东的扣除非经常性损益的净利润4.29亿元,同比增长402.43%。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1203996.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["002399","09989"],"gpt_icon":0},{"id":"2479273390","title":"《业绩》海普瑞(09989.HK)首三季纯利大增逾4.4倍至7.8亿人币","url":"https://stock-news.laohu8.com/highlight/detail?id=2479273390","media":"阿斯达克财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2479273390?lang=zh_cn&edition=full","pubTime":"2024-10-30 17:33","pubTimestamp":1730280780,"startTime":"0","endTime":"0","summary":"海普瑞公布,按中国企业会计准则,截至9月底,首三季营业收入为40.7亿元人民币(下同),按年微增0.14%,纯利达7.8亿元,按年大增444.89%,基本每股收益为0.5317元。公司指,是因为期内费用支出减少以及投资收益增加所致。过往派息公布日期派息事项派息内容2024/08/30中期业绩无派息2024/04/29第一季业绩无派息2024/03/28末期业绩无派息2023/10/30第三季业绩无派息而单计第三季,营业收入为12.3亿元,按年跌8.8%,纯利1.16亿元,按年大升487.43%,基本每股收益为0.0794元。","market":"other","thumbnail":"https://plib.aastocks.com/aafnnews/image/medialib/20201207095529647_s.jpg","type":0,"news_type":0,"thumbnails":["https://plib.aastocks.com/aafnnews/image/medialib/20201207095529647_s.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.aastocks.com/tc/stocks/news/aafn-con/NOW.1392520/latest-news/AAFN","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"aastocks_highlight","symbols":["BK0188","BK0070","002399","09989","BK1191","BK0239"],"gpt_icon":0},{"id":"2479278354","title":"海普瑞(09989)发布前三季度业绩 归母净利润7.8亿元 同比增加444.89%","url":"https://stock-news.laohu8.com/highlight/detail?id=2479278354","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2479278354?lang=zh_cn&edition=full","pubTime":"2024-10-30 17:28","pubTimestamp":1730280537,"startTime":"0","endTime":"0","summary":"智通财经APP讯,海普瑞(09989)发布2024年第三季度报告,该集团期内取得营业收入40.69亿元(人民币,下同),同比增加0.14%;归母净利润7.8亿元,同比增加444.89%;基本每股收益0.5317元。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1203689.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["002399","09989"],"gpt_icon":0},{"id":"2474296156","title":"海普瑞(09989)下跌10.6%,报4.3元/股","url":"https://stock-news.laohu8.com/highlight/detail?id=2474296156","media":"金融界","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2474296156?lang=zh_cn&edition=full","pubTime":"2024-10-09 14:56","pubTimestamp":1728457018,"startTime":"0","endTime":"0","summary":"10月9日,海普瑞(09989)盘中下跌10.6%,截至14:56,报4.3元/股,成交2456.71万元。深圳市海普瑞药业集团股份有限公司的主要业务是覆盖肝素全产业链、生物大分子CDMO以及创新药物的投资、开发和商业化。通过这三大板块业务的相互协作,公司旨在为全球患者提供安全有效的高质量药物和服务。截至2024年中报,海普瑞营业总收入28.29亿元、净利润6.64亿元。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://hk.jrj.com.cn/2024/10/09145643824365.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_stock","symbols":["BK0070","BK0239","09989","002399","BK0188","BK1191"],"gpt_icon":0},{"id":"2473457706","title":"海普瑞(09989)出现大手卖出78.95万股,成交价$5.59,涉资441.33万","url":"https://stock-news.laohu8.com/highlight/detail?id=2473457706","media":"阿斯达克财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2473457706?lang=zh_cn&edition=full","pubTime":"2024-10-08 09:20","pubTimestamp":1728350400,"startTime":"0","endTime":"0","summary":"[大手成交]海普瑞(09989)在上午09:20出现大手卖出,成交量为78.95万,成交价为港币$5.59,涉资441.33万。至目前为止,股价升1.085%,今日最高价为$5.59,而最低价为$5.59,总成交量为78.95万股,总成交金额港币$441.33万。","market":"fut","thumbnail":"https://plib.aastocks.com/aafnnews/image/medialib/20180205145549237_s.jpg","type":0,"news_type":0,"thumbnails":["https://plib.aastocks.com/aafnnews/image/medialib/20180205145549237_s.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.aastocks.com/tc/stocks/news/aamm-content/AAV241008127/aamm-all-category","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"aastocks_highlight","symbols":["BK1191","BK0239","002399","09989","BK0070","BK0188"],"gpt_icon":0},{"id":"2473145215","title":"海普瑞(09989)股价显著上升12.179%,现价港币$5.25","url":"https://stock-news.laohu8.com/highlight/detail?id=2473145215","media":"阿斯达克财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2473145215?lang=zh_cn&edition=full","pubTime":"2024-10-07 11:50","pubTimestamp":1728273000,"startTime":"0","endTime":"0","summary":"[上升股]海普瑞(09989) 股价在上午11:50比前收市价显著上升12.179%,现股价为港币$5.25。至目前为止,今日最高价为$5.25,而最低价为$4.7。总成交量为146.55万股,总成交金额为港币$735.282万。","market":"other","thumbnail":"https://plib.aastocks.com/aafnnews/image/medialib/20180126133719348_s.jpg","type":0,"news_type":0,"thumbnails":["https://plib.aastocks.com/aafnnews/image/medialib/20180126133719348_s.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.aastocks.com/tc/stocks/news/aamm-content/AAR2410074969/aamm-all-category","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"aastocks_highlight","symbols":["BK0188","BK0070","002399","09989","BK1191","BK0239"],"gpt_icon":0},{"id":"2471457908","title":"海普瑞(09989)上涨10.16%,报4.12元/股","url":"https://stock-news.laohu8.com/highlight/detail?id=2471457908","media":"金融界","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2471457908?lang=zh_cn&edition=full","pubTime":"2024-09-30 11:50","pubTimestamp":1727668252,"startTime":"0","endTime":"0","summary":"9月30日,海普瑞(09989)盘中上涨10.16%,截至11:50,报4.12元/股,成交1449.52万元。深圳市海普瑞药业集团股份有限公司的主要业务是覆盖肝素全产业链、生物大分子CDMO以及创新药物的投资、开发和商业化。通过这三大板块业务的相互协作,公司旨在为全球患者提供安全有效的高质量药物和服务。截至2024年中报,海普瑞营业总收入28.29亿元、净利润6.64亿元。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://hk.jrj.com.cn/2024/09/30115043647586.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_stock","symbols":["BK1191","BK0188","BK0239","09989","002399","BK0070"],"gpt_icon":0},{"id":"2468807964","title":"大摩:维持海普瑞“与大市同步”评级 目标价降至3.5港元","url":"https://stock-news.laohu8.com/highlight/detail?id=2468807964","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2468807964?lang=zh_cn&edition=full","pubTime":"2024-09-17 11:36","pubTimestamp":1726544178,"startTime":"0","endTime":"0","summary":"摩根士丹利发布研究报告称,削海普瑞(09989)目标价5.4%,从3.7港元降至3.5港元,基本假设为该公司2022-2025年间收入及经常性盈利的复合年增长率(CAGR)分别下降7%和5%,维持“与大市同步”评 ...","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://stock.10jqka.com.cn/hks/20240917/c661745332.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tonghuashun","symbols":["002399"],"gpt_icon":0},{"id":"2468807830","title":"大摩:维持海普瑞(09989)“与大市同步”评级 目标价降至3.5港元","url":"https://stock-news.laohu8.com/highlight/detail?id=2468807830","media":"智通财经网","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2468807830?lang=zh_cn&edition=full","pubTime":"2024-09-17 11:22","pubTimestamp":1726543362,"startTime":"0","endTime":"0","summary":"大摩上调对海普瑞(09989)2024年盈利预测7%。","market":"sh","thumbnail":"https://img.zhitongcaijing.com/image/20240917/20240917112312_18922.png?x-oss-process=image/format,jpg/quality,Q_80/resize,w_250","type":0,"news_type":0,"thumbnails":["https://img.zhitongcaijing.com/image/20240917/20240917112312_18922.png?x-oss-process=image/format,jpg/quality,Q_80/resize,w_250"],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1183745.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"highlight_zhitongcaijin","symbols":["09989","002399"],"gpt_icon":0},{"id":"2466749133","title":"海普瑞新提交2件商标注册申请","url":"https://stock-news.laohu8.com/highlight/detail?id=2466749133","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2466749133?lang=zh_cn&edition=full","pubTime":"2024-09-09 13:55","pubTimestamp":1725861321,"startTime":"0","endTime":"0","summary":"证券之星消息,根据企查查数据显示,近日深圳市海普瑞药业集团股份有限公司新提交2件商标注册申请。商标申请详情如下:今年以来深圳市海普瑞药业集团股份有限公司新申请注册商标3件,截止目前公司共持有注册商标149件,另有4件商标尚在注册申请中。数据来源:企查查以上内容为证券之星据公开信息整理,由智能算法生成,不构成投资建议。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024090900012498.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0070","002399","BK1191","09989","BK0188","BK0239"],"gpt_icon":0},{"id":"2466097209","title":"营收利润双增长,剖析海普瑞(002399.SZ/9989.HK)稳中求进的增长底色","url":"https://stock-news.laohu8.com/highlight/detail?id=2466097209","media":"格隆汇","labels":["viewpoints"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2466097209?lang=zh_cn&edition=full","pubTime":"2024-09-09 09:05","pubTimestamp":1725843935,"startTime":"0","endTime":"0","summary":"不断完善肝素全产业链核心业务,并快速提升CDMO业务的盈利能力,持续推进创新药的研发及商业化","market":"sg","thumbnail":"https://img7.gelonghui.com/column/6.png","type":0,"news_type":0,"thumbnails":["https://img7.gelonghui.com/column/6.png"],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.gelonghui.com/p/1016448","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"viewpoints","news_rank":0,"length":0,"strategy_id":0,"source":"gelonghui_highlight","symbols":["09989","002399"],"gpt_icon":0},{"id":"2464393406","title":"海普瑞(002399)9月3日主力资金净卖出100.34万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2464393406","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2464393406?lang=zh_cn&edition=full","pubTime":"2024-09-04 09:25","pubTimestamp":1725413145,"startTime":"0","endTime":"0","summary":"证券之星消息,截至2024年9月3日收盘,海普瑞报收于9.81元,下跌0.71%,换手率0.45%,成交量5.56万手,成交额5497.1万元。近5日资金流向一览见下表:海普瑞融资融券信息显示,融资方面,当日融资买入200.49万元,融资偿还244.25万元,融资净偿还43.76万元。海普瑞主营业务:肝素产业链、生物大分子CDMO和创新药物的投资、开发及商业化,致力于为全球患者带去高质量的安全有效药物和服务,护佑健康。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024090400009266.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["09989","BK0070","002399","BK0188","BK1191","BK0239"],"gpt_icon":0},{"id":"2464897643","title":"海普瑞(002399)9月2日主力资金净卖出346.82万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2464897643","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2464897643?lang=zh_cn&edition=full","pubTime":"2024-09-03 09:14","pubTimestamp":1725326065,"startTime":"0","endTime":"0","summary":"证券之星消息,截至2024年9月2日收盘,海普瑞报收于9.88元,上涨1.44%,换手率0.69%,成交量8.63万手,成交额8515.74万元。近5日资金流向一览见下表:海普瑞融资融券信息显示,融资方面,当日融资买入432.18万元,融资偿还475.92万元,融资净偿还43.73万元。海普瑞主营业务:肝素产业链、生物大分子CDMO和创新药物的投资、开发及商业化,致力于为全球患者带去高质量的安全有效药物和服务,护佑健康。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024090300008114.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0070","002399","BK1191","09989","BK0188","BK0239"],"gpt_icon":0},{"id":"2464068071","title":"《业绩》海普瑞(09989.HK)中期纯利6.64亿人民币增4.38倍 不派息","url":"https://stock-news.laohu8.com/highlight/detail?id=2464068071","media":"阿斯达克财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2464068071?lang=zh_cn&edition=full","pubTime":"2024-09-01 13:07","pubTimestamp":1725167220,"startTime":"0","endTime":"0","summary":"海普瑞(09989.HK) 公布6月止六个月中期业绩,收入28.29亿人民币(下同),按年增加4.5%;毛利9.99亿元,上升4.2%。录得纯利6.64亿元,增长4.38倍,每股盈利45分。不派中期息。(de/d)(港股报价延迟最少十五分钟。)过往派息公布日期派息事项派息内容2024/04/29第一季业绩无派息2024/03/28末期业绩无派息2023/10/30第三季业绩无派息2023/08/30中期业绩无派息AASTOCKS新闻","market":"fut","thumbnail":"https://plib.aastocks.com/aafnnews/image/medialib/20200623170857780_s.jpg","type":0,"news_type":0,"thumbnails":["https://plib.aastocks.com/aafnnews/image/medialib/20200623170857780_s.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.aastocks.com/tc/stocks/news/aafn-con/NOW.1377916/latest-news/AAFN","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"aastocks_highlight","symbols":["BK1191","BK0188","09989","002399","BK0239","BK0070"],"gpt_icon":0},{"id":"2464928039","title":"海普瑞(002399)2024年中报简析:营收净利润同比双双增长","url":"https://stock-news.laohu8.com/highlight/detail?id=2464928039","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2464928039?lang=zh_cn&edition=full","pubTime":"2024-09-01 06:16","pubTimestamp":1725142617,"startTime":"0","endTime":"0","summary":"据证券之星公开数据整理,近期海普瑞发布2024年中报。根据财报显示,海普瑞营收净利润同比双双增长。截至本报告期末,公司营业总收入28.37亿元,同比上升4.59%,归母净利润6.64亿元,同比上升438.05%。其中,毛利率34.83%,同比减1.16%,净利率23.36%,同比增417.92%,销售费用、管理费用、财务费用总计4.6亿元,三费占营收比16.22%,同比减12.61%,每股净资产8.27元,同比减2.12%,每股经营性现金流0.88元,同比增338.57%,每股收益0.45元,同比增437.81%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024090100001042.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["002399","09989"],"gpt_icon":0},{"id":"2463984734","title":"海普瑞最新公告:上半年净利润6.64亿元 同比增长438.05%","url":"https://stock-news.laohu8.com/highlight/detail?id=2463984734","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2463984734?lang=zh_cn&edition=full","pubTime":"2024-08-30 20:21","pubTimestamp":1725020493,"startTime":"0","endTime":"0","summary":"海普瑞披露半年报,公司上半年实现营业收入28.37亿元,同比增长4.59%;净利润6.64亿元,同比增长438.05%;基本每股收益0.45元。报告期内,公司肝素制剂业务发展态势向好,依诺肝素钠制剂在海外及国内市场的销量保持增长,全球市场占有率进一步提升。以上内容为证券之星据公开信息整理,由智能算法生成,不构成投资建议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024083000044045.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["09989","002399"],"gpt_icon":0}],"profile":{"ret":0,"listingDate":"2010-05-06","address":"广东省深圳市南山区松坪山郎山路21号","stockEarnings":[{"period":"1week","weight":0.0116},{"period":"1month","weight":0.0098},{"period":"3month","weight":0.1793},{"period":"6month","weight":0.1369},{"period":"1year","weight":-0.0968},{"period":"ytd","weight":-0.0298}],"companyName":"深圳市海普瑞药业集团股份有限公司","boardCode":"AI0027","perCapita":"--","boardName":"医药制造业","registeredCapital":"146729万元","compareEarnings":[{"period":"1week","weight":-0.0028},{"period":"1month","weight":0.0257},{"period":"3month","weight":0.1808},{"period":"6month","weight":0.0911},{"period":"1year","weight":0.1074},{"period":"ytd","weight":0.1329}],"survey":" 深圳市海普瑞药业集团股份有限公司是一家从事肝素产业链、生物大分子CDMO和创新药物的投资、开发和商业化的企业。主要产品和服务包括依诺肝素钠制剂、肝素钠和依诺肝素钠原料药,以及大分子药物CDMO服务。本公司是全球产销规模最大、也是我国唯一同时取得美国FDA认证和欧盟CEP认证的肝素钠原料药生产企业。公司作为欧盟依诺肝素生物类似物市场的先驱者,公司已在知名医院以及医学专家中树立了良好的品牌声誉。","serverTime":1732283943358,"listedPrice":148,"stockholders":"0人","compareStock":{"symbol":"000001.SH","name":"上证指数"}},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.29.2","shortVersion":"4.29.2","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"海普瑞(002399)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供海普瑞(002399)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"海普瑞,002399,海普瑞股票,海普瑞股票老虎,海普瑞股票老虎国际,海普瑞行情,海普瑞股票行情,海普瑞股价,海普瑞股市,海普瑞股票价格,海普瑞股票交易,海普瑞股票购买,海普瑞股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"海普瑞(002399)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供海普瑞(002399)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}